Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03513406 · ClinicalTrials.gov registry record · Phase 3
Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery
A Phase 3 study of Burns, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT03513406 is a Phase 3 study of Burns that has completed, run by University of Kansas Medical Center. The registered enrollment target is 7 participants, below the 83-participant average among 36 other Burns trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03513406, a Phase 3 study of Burns, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn if there is a difference in recovery time when using sugammadex versus neostigmine. The researchers also hope to add further knowledge and data to the safety of using sugammadex in burn patients who are hypermetabolic.
Conditions Studied
Interventions
- DRUG Sugammadex
- DRUG Neostigmine
- DRUG Glycopyrrolate
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-03-15 |
| Est. Completion | 2023-03-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03513406
The ClinicalTrials.gov registry entry for NCT03513406 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 36 other Burns trials with a reported enrollment target (92% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Burns appearing as the primary indexed condition, and to 3 interventions - of which Sugammadex is the first listed.
NCT03513406 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT03513406 about?
NCT03513406 is a clinical study titled "Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery". The purpose of this study is to learn if there is a difference in recovery time when using sugammadex versus neostigmine. The researchers also hope to add further knowledge and data to the safety of using sugammadex in burn patients who are hypermetabolic.
What is the current status of trial NCT03513406?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2018-03-15. Estimated completion is 2023-03-07.
What conditions does trial NCT03513406 study?
This clinical trial studies the following conditions: Burns.
What interventions are being tested in trial NCT03513406?
The interventions under investigation include: Sugammadex (DRUG), Neostigmine (DRUG), Glycopyrrolate (DRUG).
Who is sponsoring clinical trial NCT03513406?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03513406 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Burns
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing
COMPLETED · Phase 3
-
Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn
COMPLETED · Phase 3
-
StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects
COMPLETED · Phase 3
-
Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds
RECRUITING · NA
-
Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain
RECRUITING · Phase 4
-
Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.